Tags: Drug Discovery


New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.


$2.5 Million in New Funding Exemplifies ADDF’s Strategy

We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease. 


ADDF and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award

Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.


Funding Supports New Approaches to Treat Multiple Types of Dementia

The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.


Three New Grants Keep Promising Programs Forging Ahead

The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.


New Project Co-Funded with Pfizer’s Centers for Therapeutic Innovation

The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced joint support for a project that could result in a therapeutic for neurodegenerative diseases.


New Funding Supports Blood Test for Early Alzheimer’s

The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.


Inflammation, The Driver of Alzheimer's Disease?

A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.


Latest Funding Includes Support for Innovative Clinical Trial

The ADDF announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.


2016 Annual Report Released

The 2016 Annual Report, titled “From Idea to Impact,” highlights the enormous progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.